Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Int J Hematol

Retrieve available abstracts of 110 articles:
HTML format
Text format



Single Articles


    October 2018
  1. HARADA K, Sekiya N, Ikegawa S, Sasaki S, et al
    Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia.
    Int J Hematol. 2018 Oct 5. pii: 10.1007/s12185-018-2544.
    PubMed     Text format     Abstract available


    September 2018
  2. AZEVEDO PORTILHO N, Kobayashi M, Yoshimoto M
    What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells.
    Int J Hematol. 2018 Sep 27. pii: 10.1007/s12185-018-2537.
    PubMed     Text format     Abstract available


    August 2018
  3. MINAMI Y
    Guest editorial: chronic myeloid leukemia.
    Int J Hematol. 2018 Aug 28. pii: 10.1007/s12185-018-2521.
    PubMed     Text format    


  4. INOUE A, Kobayashi CI, Shinohara H, Miyamoto K, et al
    Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
    Int J Hematol. 2018 Aug 28. pii: 10.1007/s12185-018-2519.
    PubMed     Text format     Abstract available


  5. WATANABE N, Takaku T, Takeda K, Shirane S, et al
    Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
    Int J Hematol. 2018 Aug 27. pii: 10.1007/s12185-018-2517.
    PubMed     Text format     Abstract available


  6. TAN TK, Zhang C, Sanda T
    Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia.
    Int J Hematol. 2018 Aug 25. pii: 10.1007/s12185-018-2518.
    PubMed     Text format     Abstract available


  7. KANAYAMA T, Imamura T, Kawabe Y, Osone S, et al
    KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
    Int J Hematol. 2018 Aug 24. pii: 10.1007/s12185-018-2522.
    PubMed     Text format     Abstract available


  8. SATO K, Sakai H, Saiki Y, Uchida A, et al
    Correction to: Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.
    Int J Hematol. 2018 Aug 12. pii: 10.1007/s12185-018-2515.
    PubMed     Text format     Abstract available


  9. CHIBA A, Toya T, Mizuno H, Tokushige J, et al
    Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.
    Int J Hematol. 2018 Aug 4. pii: 10.1007/s12185-018-2511.
    PubMed     Text format     Abstract available


    July 2018
  10. ITAMURA H, Ide M, Sato A, Sueoka-Aragane N, et al
    Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.
    Int J Hematol. 2018 Jul 24. pii: 10.1007/s12185-018-2506.
    PubMed     Text format     Abstract available


  11. NAKASHIMA J, Imaizumi Y, Taniguchi H, Ando K, et al
    Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
    Int J Hematol. 2018 Jul 21. pii: 10.1007/s12185-018-2509.
    PubMed     Text format     Abstract available


  12. KURATA K, Nishimura S, Ichikawa H, Sakai R, et al
    Invasive Scopulariopsis alboflavescens infection in patient with acute myeloid leukemia.
    Int J Hematol. 2018 Jul 9. pii: 10.1007/s12185-018-2496.
    PubMed     Text format     Abstract available


    June 2018
  13. TAKEI H, Kobayashi SS
    Targeting transcription factors in acute myeloid leukemia.
    Int J Hematol. 2018 Jun 28. pii: 10.1007/s12185-018-2488.
    PubMed     Text format     Abstract available


  14. HASSAN IB, Kristensen J, Al Qawasmeh K, Alam A, et al
    Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates.
    Int J Hematol. 2018 Jun 27. pii: 10.1007/s12185-018-2478.
    PubMed     Text format     Abstract available


  15. ORAVCOVA I, Mikuskova E, Leitnerova M, Gyarfas J, et al
    A unique clinical presentation of de novo acute promyelocytic leukemia as a myeloid sarcoma of the breast.
    Int J Hematol. 2018 Jun 21. pii: 10.1007/s12185-018-2479.
    PubMed     Text format     Abstract available


  16. KAWAI H, Matsushita H, Aoyama Y, Matsui K, et al
    Correction to: Dysplastic features seen in a patient with acute myeloid leukemia harboring the KMT2A-TET1 fusion gene.
    Int J Hematol. 2018 Jun 12. pii: 10.1007/s12185-018-2476.
    PubMed     Text format     Abstract available


  17. WILKINSON AC, Yamazaki S
    The hematopoietic stem cell diet.
    Int J Hematol. 2018;107:634-641.
    PubMed     Text format     Abstract available


    May 2018
  18. SATO K, Sakai H, Saiki Y, Uchida A, et al
    Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.
    Int J Hematol. 2018 May 29. pii: 10.1007/s12185-018-2472.
    PubMed     Text format     Abstract available


  19. TOMOYASU C, Imamura T, Tomii T, Yano M, et al
    Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
    Int J Hematol. 2018 May 21. pii: 10.1007/s12185-018-2474.
    PubMed     Text format     Abstract available


  20. KAWAI H, Matsushita H, Aoyama Y, Matsui K, et al
    Dysplastic features seen in a patient with acute myeloid leukemia harboring the KTM2A-TET1 fusion gene.
    Int J Hematol. 2018 May 9. pii: 10.1007/s12185-018-2469.
    PubMed     Text format    


  21. GOTOH N, Saitoh T, Takahashi N, Kasamatsu T, et al
    Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia.
    Int J Hematol. 2018 May 8. pii: 10.1007/s12185-018-2464.
    PubMed     Text format     Abstract available


  22. ISHIKAWA J, Matsumura I, Kawaguchi T, Kuroda J, et al
    Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
    Int J Hematol. 2018;107:535-540.
    PubMed     Text format     Abstract available


    April 2018
  23. NOGUCHI S, Nakaseko C, Nishiwaki K, Ogasawara H, et al
    Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
    Int J Hematol. 2018 Apr 30. pii: 10.1007/s12185-018-2459.
    PubMed     Text format     Abstract available


  24. TORIYAMA E, Imaizumi Y, Taniguchi H, Taguchi J, et al
    EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.
    Int J Hematol. 2018 Apr 12. pii: 10.1007/s12185-018-2455.
    PubMed     Text format     Abstract available


    March 2018
  25. WATANABE J, Sato K, Osawa Y, Horiuchi T, et al
    CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
    Int J Hematol. 2018 Mar 29. pii: 10.1007/s12185-018-2436.
    PubMed     Text format     Abstract available


  26. TAKAHASHI H, Kajiwara R, Kato M, Hasegawa D, et al
    Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16.
    Int J Hematol. 2018 Mar 27. pii: 10.1007/s12185-018-2440.
    PubMed     Text format     Abstract available


  27. IMAMURA T, Taga T, Takagi M, Kawasaki H, et al
    Nationwide survey of therapy-related leukemia in childhood in Japan.
    Int J Hematol. 2018 Mar 24. pii: 10.1007/s12185-018-2439.
    PubMed     Text format     Abstract available


  28. SANO H, Kobayashi R, Suzuki D, Hori D, et al
    Impact of the D-index deduced from duration and intensity of neutropenia following chemotherapy on the risk of invasive fungal infection in pediatric acute myeloid leukemia.
    Int J Hematol. 2018 Mar 21. pii: 10.1007/s12185-018-2433.
    PubMed     Text format     Abstract available


  29. SANO H, Mochizuki K, Kobayashi S, Ohara Y, et al
    T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.
    Int J Hematol. 2018 Mar 5. pii: 10.1007/s12185-018-2423.
    PubMed     Text format     Abstract available


  30. MIYOSHI H, Ohshima K
    Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan.
    Int J Hematol. 2018 Mar 3. pii: 10.1007/s12185-018-2430.
    PubMed     Text format     Abstract available


  31. KAWAMOTO H, Masuda K, Nagano S, Maeda T, et al
    Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.
    Int J Hematol. 2018;107:271-277.
    PubMed     Text format     Abstract available


    February 2018
  32. SUEMATSU M, Imamura T, Chiyonobu T, Osone S, et al
    Lumbosacral polyradiculopathy after intrathecal chemotherapy in pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2018 Feb 22. pii: 10.1007/s12185-018-2427.
    PubMed     Text format    


  33. NAQVI K, Cortes JE, Luthra R, O'Brien S, et al
    Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
    Int J Hematol. 2018 Feb 20. pii: 10.1007/s12185-018-2422.
    PubMed     Text format     Abstract available


  34. SATO S, Itonaga H, Taguchi M, Sawayama Y, et al
    Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.
    Int J Hematol. 2018 Feb 7. pii: 10.1007/s12185-018-2419.
    PubMed     Text format     Abstract available


  35. SCHROEDER T, Rautenberg C, Haas R, Germing U, et al
    Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.
    Int J Hematol. 2018;107:138-150.
    PubMed     Text format     Abstract available


  36. KOIZUMI Y, Furuya D, Endo T, Asanuma K, et al
    Quantification of Wilms' tumor 1 mRNA by digital polymerase chain reaction.
    Int J Hematol. 2018;107:230-234.
    PubMed     Text format     Abstract available


    January 2018
  37. TAKAMI A
    Hematopoietic stem cell transplantation for acute myeloid leukemia.
    Int J Hematol. 2018 Jan 27. pii: 10.1007/s12185-018-2412.
    PubMed     Text format     Abstract available


  38. SHIMADA A, Iijima-Yamashita Y, Tawa A, Tomizawa D, et al
    Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Int J Hematol. 2018 Jan 12. pii: 10.1007/s12185-017-2395.
    PubMed     Text format     Abstract available


    December 2017
  39. ABE A, Yamamoto Y, Katsumi A, Okamoto A, et al
    Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21).
    Int J Hematol. 2017 Dec 20. pii: 10.1007/s12185-017-2387.
    PubMed     Text format     Abstract available


  40. MIYAMOTO T, Nagafuji K, Fujisaki T, Uchida N, et al
    Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
    Int J Hematol. 2017 Dec 14. pii: 10.1007/s12185-017-2389.
    PubMed     Text format     Abstract available


  41. SUZUKI D, Kobayashi R, Sano H, Hori D, et al
    Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance.
    Int J Hematol. 2017 Dec 12. pii: 10.1007/s12185-017-2388.
    PubMed     Text format     Abstract available


    November 2017
  42. FUJIMAKI K, Hattori Y, Nakajima H
    10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation.
    Int J Hematol. 2017 Nov 29. pii: 10.1007/s12185-017-2382.
    PubMed     Text format     Abstract available


  43. KIKUCHI J, Kuroda Y, Koyama D, Furukawa Y, et al
    Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells.
    Int J Hematol. 2017 Nov 28. pii: 10.1007/s12185-017-2376.
    PubMed     Text format    


  44. FUJIWARA SI, Shirato Y, Ikeda T, Kawaguchi SI, et al
    Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Int J Hematol. 2017 Nov 28. pii: 10.1007/s12185-017-2378.
    PubMed     Text format     Abstract available


  45. YAMAMOTO M, Hori T, Igarashi K, Iesato K, et al
    Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2017 Nov 27. pii: 10.1007/s12185-017-2377.
    PubMed     Text format    


  46. UEMURA S, Nishimura N, Hasegawa D, Shono A, et al
    ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
    Int J Hematol. 2017 Nov 24. pii: 10.1007/s12185-017-2371.
    PubMed     Text format     Abstract available


    October 2017
  47. COOK LB, Rowan AG, Demontis MA, Sagawe S, et al
    Long-term clinical remission maintained after cessation of zidovudine and interferon-alpha therapy in chronic adult T-cell leukemia/lymphoma.
    Int J Hematol. 2017 Oct 31. doi: 10.1007/s12185-017-2361.
    PubMed     Text format     Abstract available


  48. NAKAMAE H, Fukuda T, Nakaseko C, Kanda Y, et al
    Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
    Int J Hematol. 2017 Oct 26. doi: 10.1007/s12185-017-2353.
    PubMed     Text format     Abstract available


  49. TAKEUCHI J, Kusumoto S, Akiyama H, Kanda Y, et al
    JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 3. Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
    Int J Hematol. 2017 Oct 24. doi: 10.1007/s12185-017-2350.
    PubMed     Text format    


  50. HONG CR, Kang HJ, Park KD, Shin HY, et al
    High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia.
    Int J Hematol. 2017 Oct 20. doi: 10.1007/s12185-017-2355.
    PubMed     Text format     Abstract available


  51. KOZAKAI T, Takahashi M, Higuchi M, Hara T, et al
    MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia.
    Int J Hematol. 2017 Oct 17. doi: 10.1007/s12185-017-2359.
    PubMed     Text format     Abstract available


  52. KOBAYASHI N, Shimizu H, Hirato J, Handa H, et al
    Collision of metastatic malignant melanoma and acute myelogenous leukemia in the bone marrow.
    Int J Hematol. 2017 Oct 17. doi: 10.1007/s12185-017-2356.
    PubMed     Text format    


  53. OKADA Y, Sato K, Kobayashi S, Nagao S, et al
    Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved.
    Int J Hematol. 2017 Oct 14. doi: 10.1007/s12185-017-2354.
    PubMed     Text format     Abstract available


  54. ISHIDA T, Akagawa N, Miyata T, Tominaga N, et al
    Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia.
    Int J Hematol. 2017 Oct 13. doi: 10.1007/s12185-017-2339.
    PubMed     Text format     Abstract available


  55. WANG Y, Xing Y, Chen L, Meng T, et al
    Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis.
    Int J Hematol. 2017 Oct 13. doi: 10.1007/s12185-017-2342.
    PubMed     Text format     Abstract available


  56. USUI N
    Correction to: JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2017 Oct 12. doi: 10.1007/s12185-017-2351.
    PubMed     Text format     Abstract available


  57. KUWATSUKA Y, Tomizawa D, Kihara R, Nagata Y, et al
    Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
    Int J Hematol. 2017 Oct 12. doi: 10.1007/s12185-017-2340.
    PubMed     Text format     Abstract available


    September 2017
  58. USUI N
    JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2017 Sep 21. doi: 10.1007/s12185-017-2330.
    PubMed     Text format    


  59. TAKAHASHI N, Tauchi T, Kitamura K, Miyamura K, et al
    Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
    Int J Hematol. 2017 Sep 19. doi: 10.1007/s12185-017-2334.
    PubMed     Text format     Abstract available


  60. KOBAYASHI Y, Munakata W, Ogura M, Uchida T, et al
    Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Int J Hematol. 2017 Sep 13. doi: 10.1007/s12185-017-2327.
    PubMed     Text format     Abstract available


  61. DELIA D, Mizutani S
    The DNA damage response pathway in normal hematopoiesis and malignancies.
    Int J Hematol. 2017;106:328-334.
    PubMed     Text format     Abstract available


    August 2017
  62. ASOU N, Fujita H, Shinagawa K
    JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia: 2. Acute promyelocytic leukemia (APL).
    Int J Hematol. 2017 Aug 30. doi: 10.1007/s12185-017-2318.
    PubMed     Text format    


  63. KOTAKI R, Higuchi H, Ogiya D, Katahira Y, et al
    Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.
    Int J Hematol. 2017 Aug 22. doi: 10.1007/s12185-017-2314.
    PubMed     Text format     Abstract available


  64. HAN DM, Zheng XL, Ding L, Yan HM, et al
    Risk factors in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk childhood acute leukemia.
    Int J Hematol. 2017 Aug 20. doi: 10.1007/s12185-017-2317.
    PubMed     Text format     Abstract available


  65. HARA R, Onizuka M, Matsusita E, Kikkawa E, et al
    NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.
    Int J Hematol. 2017 Aug 9. doi: 10.1007/s12185-017-2294.
    PubMed     Text format     Abstract available


  66. MIYAWAKI S
    JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML).
    Int J Hematol. 2017 Aug 7. doi: 10.1007/s12185-017-2303.
    PubMed     Text format    


  67. FEURSTEIN S, Godley LA
    Germline ETV6 mutations and predisposition to hematological malignancies.
    Int J Hematol. 2017;106:189-195.
    PubMed     Text format     Abstract available


  68. CHEAH JJC, Hahn CN, Hiwase DK, Scott HS, et al
    Myeloid neoplasms with germline DDX41 mutation.
    Int J Hematol. 2017;106:163-174.
    PubMed     Text format     Abstract available


  69. HAYASHI Y, Harada Y, Huang G, Harada H, et al
    Myeloid neoplasms with germ line RUNX1 mutation.
    Int J Hematol. 2017;106:183-188.
    PubMed     Text format     Abstract available


  70. HUA Y, Wang C, Jiang H, Wang Y, et al
    Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.
    Int J Hematol. 2017;106:248-257.
    PubMed     Text format     Abstract available


    July 2017
  71. GEYER JT, Mathew S
    Myelomonocytic leukemia with intracytoplasmic crystalline inclusions, double minute chromosomes and MYC amplification.
    Int J Hematol. 2017 Jul 28. doi: 10.1007/s12185-017-2299.
    PubMed     Text format    


  72. DI IANNI M, Olioso P, Giancola R, Santarone S, et al
    Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.
    Int J Hematol. 2017 Jul 18. doi: 10.1007/s12185-017-2292.
    PubMed     Text format     Abstract available


  73. REA D, Cayuela JM
    Treatment-free remission in patients with chronic myeloid leukemia.
    Int J Hematol. 2017 Jul 8. doi: 10.1007/s12185-017-2295.
    PubMed     Text format     Abstract available


  74. HIRANO M, Ohno N, Tanosaki R, Mochizuki M, et al
    Adult T-cell leukemia cell-induced uveitis: rapid increase in adult T-cell leukemia cells disrupts the blood-ocular barrier.
    Int J Hematol. 2017 Jul 4. doi: 10.1007/s12185-017-2293.
    PubMed     Text format     Abstract available


  75. MIYAZAKI Y
    JSH Guideline for Tumors of Hematopoietic and Lymphoid Tissues: Leukemia: 6. Myelodysplastic syndromes (MDS).
    Int J Hematol. 2017 Jul 4. doi: 10.1007/s12185-017-2272.
    PubMed     Text format    


  76. UEMURA S, Tamura A, Saito A, Hasegawa D, et al
    Reemergence of translocation t(11;19)(q23;p13.1) in the absence of clinically overt leukemia.
    Int J Hematol. 2017 Jul 1. doi: 10.1007/s12185-017-2289.
    PubMed     Text format     Abstract available


  77. KUNIMOTO H, Nakajima H
    Epigenetic dysregulation of hematopoietic stem cells and preleukemic state.
    Int J Hematol. 2017;106:34-44.
    PubMed     Text format     Abstract available


  78. KARIGANE D, Takubo K
    Metabolic regulation of hematopoietic and leukemic stem/progenitor cells under homeostatic and stress conditions.
    Int J Hematol. 2017;106:18-26.
    PubMed     Text format     Abstract available


  79. MATSUO H, Shiga S, Imai T, Kamikubo Y, et al
    Purification of leukemic blast cells from blood smears using laser microdissection.
    Int J Hematol. 2017;106:55-59.
    PubMed     Text format     Abstract available


    June 2017
  80. TANG S, Shen H, Mao X, Dai H, et al
    FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2017 Jun 14. doi: 10.1007/s12185-017-2256.
    PubMed     Text format     Abstract available


  81. ISHITSUKA K, Yurimoto S, Kawamura K, Tsuji Y, et al
    Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
    Int J Hematol. 2017 Jun 9. doi: 10.1007/s12185-017-2270.
    PubMed     Text format     Abstract available


  82. ZHANG R, Chen J, Huang H, Ma J, et al
    Erratum to: Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study.
    Int J Hematol. 2017 Jun 2. doi: 10.1007/s12185-017-2269.
    PubMed     Text format    


  83. ITZYKSON R, Duchmann M, Lucas N, Solary E, et al
    CMML: Clinical and molecular aspects.
    Int J Hematol. 2017;105:711-719.
    PubMed     Text format     Abstract available


    May 2017
  84. TAMURA A, Uemura S, Saito A, Okubo S, et al
    Congenital immature pure erythroid leukemia with E-cadherin expression.
    Int J Hematol. 2017 May 18. doi: 10.1007/s12185-017-2248.
    PubMed     Text format     Abstract available


  85. MINAKATA D, Fujiwara SI, Ikeda T, Toda Y, et al
    Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.
    Int J Hematol. 2017 May 15. doi: 10.1007/s12185-017-2251.
    PubMed     Text format     Abstract available


  86. HANEKAMP D, Cloos J, Schuurhuis GJ
    Leukemic stem cells: identification and clinical application.
    Int J Hematol. 2017;105:549-557.
    PubMed     Text format     Abstract available


  87. TAKAGI M, Ishiwata Y, Aoki Y, Miyamoto S, et al
    HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.
    Int J Hematol. 2017;105:686-691.
    PubMed     Text format     Abstract available


  88. CAMACHO V, McClearn V, Patel S, Welner RS, et al
    Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment.
    Int J Hematol. 2017;105:566-577.
    PubMed     Text format     Abstract available


  89. IKEGAME K, Kaida K, Yoshihara S, Yoshihara K, et al
    Spousal hematopoietic stem cell transplantation.
    Int J Hematol. 2017;105:646-657.
    PubMed     Text format     Abstract available


  90. URESHINO H, Kizuka H, Kusaba K, Sano H, et al
    5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
    Int J Hematol. 2017;105:692-696.
    PubMed     Text format     Abstract available


    April 2017
  91. TOJO A, Kyo T, Yamamoto K, Nakamae H, et al
    Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.
    Int J Hematol. 2017 Apr 25. doi: 10.1007/s12185-017-2238.
    PubMed     Text format     Abstract available


  92. HATAKE K, Ogura M, Takada K, Taniwaki M, et al
    Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.
    Int J Hematol. 2017 Apr 18. doi: 10.1007/s12185-017-2233.
    PubMed     Text format     Abstract available


  93. KE S, Li RC, Lu J, Meng FK, et al
    MicroRNA-192 regulates cell proliferation and cell cycle transition in acute myeloid leukemia via interaction with CCNT2.
    Int J Hematol. 2017 Apr 13. doi: 10.1007/s12185-017-2232.
    PubMed     Text format     Abstract available


  94. TAKAHASHI N, Nakaseko C, Kobayashi Y, Miyamura K, et al
    Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
    Int J Hematol. 2017 Apr 13. doi: 10.1007/s12185-017-2239.
    PubMed     Text format     Abstract available


  95. IGUCHI A, Cho Y, Sugiyama M, Terashita Y, et al
    Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.
    Int J Hematol. 2017 Apr 11. doi: 10.1007/s12185-017-2235.
    PubMed     Text format     Abstract available


  96. ONG SY, Ho LP, Yeo PM, Ng HJ, et al
    Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia with t(8;21).
    Int J Hematol. 2017 Apr 7. doi: 10.1007/s12185-017-2230.
    PubMed     Text format    


  97. ZHANG R, Chen J, Huang H, Ma J, et al
    Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study.
    Int J Hematol. 2017 Apr 7. doi: 10.1007/s12185-017-2224.
    PubMed     Text format     Abstract available


  98. SUH KJ, Lee JY, Shin DY, Koh Y, et al
    Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
    Int J Hematol. 2017 Apr 4. doi: 10.1007/s12185-017-2225.
    PubMed     Text format     Abstract available


  99. YAGUCHI A, Ishibashi T, Terada K, Ueno-Yokohata H, et al
    EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.
    Int J Hematol. 2017 Apr 4. doi: 10.1007/s12185-017-2220.
    PubMed     Text format     Abstract available


  100. ASANO M, Umezu T, Katagiri S, Kobayashi C, et al
    Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors.
    Int J Hematol. 2017;105:419-422.
    PubMed     Text format     Abstract available


    March 2017
  101. NAKAMAE H, Fujisawa S, Ogura M, Uchida T, et al
    Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.
    Int J Hematol. 2017 Mar 24. doi: 10.1007/s12185-017-2208.
    PubMed     Text format     Abstract available


  102. BARAKA A, Sherief LM, Kamal NM, Shorbagy SE, et al
    Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
    Int J Hematol. 2017 Mar 21. doi: 10.1007/s12185-017-2206.
    PubMed     Text format     Abstract available


  103. KATZ BZ, Herishanu Y
    Fragility of sub-cellular structures in chronic lymphocytic leukemia.
    Int J Hematol. 2017 Mar 21. doi: 10.1007/s12185-017-2218.
    PubMed     Text format    


  104. LOVATO S, Ayto R
    Haemolysis in female patient with chronic phase CML.
    Int J Hematol. 2017;105:233-234.
    PubMed     Text format    


  105. KANAMITSU K, Shimada A, Nishiuchi R, Shigemura T, et al
    Pediatric intestinal Behcet disease complicated by myeloid malignancies.
    Int J Hematol. 2017;105:377-382.
    PubMed     Text format     Abstract available


    January 2017
  106. WAISBREN J, Dinner S, Altman J, Frankfurt O, et al
    Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
    Int J Hematol. 2017;105:44-51.
    PubMed     Text format     Abstract available


    November 2016
  107. UEMURA M, Imataki O, Kawachi Y, Kawakami K, et al
    Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.
    Int J Hematol. 2016;104:621-627.
    PubMed     Text format     Abstract available


  108. JUNG KS, Cho SH, Kim SJ, Ko YH, et al
    Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma.
    Int J Hematol. 2016;104:591-595.
    PubMed     Text format     Abstract available


  109. RUBIO P, Campos B, Digiorge JA, Gallego MS, et al
    NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Int J Hematol. 2016;104:582-590.
    PubMed     Text format     Abstract available


  110. MONIKA BELICKOVA M, Merkerova MD, Votavova H, Valka J, et al
    Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.
    Int J Hematol. 2016;104:566-573.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: